WO2006081337A3 - Erastine et proteines de liaison d'erastine, et utilisations de celles-ci - Google Patents

Erastine et proteines de liaison d'erastine, et utilisations de celles-ci Download PDF

Info

Publication number
WO2006081337A3
WO2006081337A3 PCT/US2006/002723 US2006002723W WO2006081337A3 WO 2006081337 A3 WO2006081337 A3 WO 2006081337A3 US 2006002723 W US2006002723 W US 2006002723W WO 2006081337 A3 WO2006081337 A3 WO 2006081337A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer cells
killing cancer
erastin
analogues
erastin analogues
Prior art date
Application number
PCT/US2006/002723
Other languages
English (en)
Other versions
WO2006081337A2 (fr
Inventor
Brent R Stockwell
Original Assignee
Whitehead Biomedical Inst
Univ Columbia
Brent R Stockwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Univ Columbia, Brent R Stockwell filed Critical Whitehead Biomedical Inst
Priority to JP2007553218A priority Critical patent/JP2008537726A/ja
Priority to US11/492,546 priority patent/US20070161644A1/en
Publication of WO2006081337A2 publication Critical patent/WO2006081337A2/fr
Publication of WO2006081337A3 publication Critical patent/WO2006081337A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des méthodes permettant de cribler des partenaires de liaison, en particulier, des partenaires de liaison essentiels pour l'activité biologique de l'érastine (par exemple, des VDAC tels que VDAC3). L'invention concerne également des réactifs et des méthodes permettant de tuer efficacement les cellules cancéreuses à l'aide de l'érastine ainsi que des composés et des dérivés correspondant.
PCT/US2006/002723 2005-01-25 2006-01-25 Erastine et proteines de liaison d'erastine, et utilisations de celles-ci WO2006081337A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007553218A JP2008537726A (ja) 2005-01-25 2006-01-25 癌細胞を殺傷するためのエラスチンアナログおよびその使用
US11/492,546 US20070161644A1 (en) 2005-01-25 2006-07-24 Erastin analogs and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64737205P 2005-01-25 2005-01-25
US60/647,372 2005-01-25
US76222106P 2006-01-24 2006-01-24
US60/762,221 2006-01-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/492,546 Continuation-In-Part US20070161644A1 (en) 2005-01-25 2006-07-24 Erastin analogs and uses thereof

Publications (2)

Publication Number Publication Date
WO2006081337A2 WO2006081337A2 (fr) 2006-08-03
WO2006081337A3 true WO2006081337A3 (fr) 2007-02-15

Family

ID=36570357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002723 WO2006081337A2 (fr) 2005-01-25 2006-01-25 Erastine et proteines de liaison d'erastine, et utilisations de celles-ci

Country Status (2)

Country Link
JP (1) JP2008537726A (fr)
WO (1) WO2006081337A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521484A (ja) * 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド ３−アリール置換キナゾロンおよびその使用
WO2008013987A2 (fr) * 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
JP5947623B2 (ja) * 2012-06-04 2016-07-06 インフォコム株式会社 抗がん剤の効果増強剤
CN103360327B (zh) * 2012-12-13 2016-04-20 中山大学 一种苯并吩嗪衍生物及其制备方法和应用
US10087175B2 (en) 2014-04-01 2018-10-02 Washington University Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
CA3073760A1 (fr) * 2017-09-05 2019-03-14 The Royal Institution For The Advancement Of Learning/Mcgill University Composes, compositions pharmaceutiques et leur utilisation en tant qu'inhibiteurs de la ran gtpase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248221A1 (en) * 2003-01-29 2004-12-09 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2006081331A2 (fr) * 2005-01-25 2006-08-03 Prolexys Pharmaceuticals, Inc. Erastine et proteines de liaison d'erastine, et utilisations de celles-ci

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248221A1 (en) * 2003-01-29 2004-12-09 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2006081331A2 (fr) * 2005-01-25 2006-08-03 Prolexys Pharmaceuticals, Inc. Erastine et proteines de liaison d'erastine, et utilisations de celles-ci

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"ComGenex Product List (Catalog)", 2005 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 2001:902538 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 2001:903613 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 May 2001 (2001-05-21), XP002405284 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 May 2001 (2001-05-21), XP002405285 *
DOLMA S ET AL: "Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells", CANCER CELL, vol. 3, March 2003 (2003-03-01), pages 285 - 296, XP002392895 *

Also Published As

Publication number Publication date
WO2006081337A2 (fr) 2006-08-03
JP2008537726A (ja) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2006124713A3 (fr) 4-biarylyl-1-phenylazetidin-2-ones
WO2006119329A3 (fr) Compositions et procedes pour traiter des maladies neurodegeneratives
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
NL2000375A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
WO2008097561A8 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
AP2344A (en) N-Thio-anthranilamid compounds and their use as pesticides.
WO2009009173A3 (fr) Klotho bêta
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2007037849A3 (fr) Compositions et methodes pour le transport intraoculaire d'agents therapeutiques
ZA200903604B (en) Methods,compositions,and kits for the treatment of medical conditions
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2006072615A3 (fr) Triazolophtalazines
WO2008112192A3 (fr) Anticorps epha3 utilises dans le traitement des tumeurs solides
NL1031845A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
WO2007001962A3 (fr) Systemes et procedes de production de materiel biologique
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2006081337A3 (fr) Erastine et proteines de liaison d'erastine, et utilisations de celles-ci
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006098998A3 (fr) Procedes et compositions de modulation de l'integrite vasculaire
WO2006015191A3 (fr) Analogues de lonidamine multicycliques
IL185997A0 (en) Substituted aryl 1.4-pyrazine derivatives background of the invention

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11492546

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 11492546

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007553218

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06733910

Country of ref document: EP

Kind code of ref document: A2